About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 340849, 19 pages
http://dx.doi.org/10.1155/2010/340849
Review Article

Inborn Errors of Energy Metabolism Associated with Myopathies

1Department of Paediatric Kidney-, Liver- and Metabolic Diseases, Hannover Medical School, Carl Neuberg Street 1, 30625 Hannover, Germany
2Screening Laboratory Hannover, Steinweg 13b, 30952 Ronnenberg, Germany

Received 29 October 2009; Revised 19 January 2010; Accepted 22 February 2010

Academic Editor: Henk L. M. Granzier

Copyright © 2010 Anibh M. Das et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Wagenmakers, “Muscle amino acid metabolism at rest and during exercise: role in human physiology and metabolism,” Exercise and Sport Sciences Reviews, vol. 26, pp. 287–314, 1998. View at Scopus
  2. E. Blomstrand and B. Essén-Gustavsson, “Changes in amino acid concentration in plasma and type I and type II fibres during resistance exercise and recovery in human subjects,” Amino Acids, vol. 37, no. 4, pp. 629–636, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. D. McGarry and N. F. Brown, “The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis,” European Journal of Biochemistry, vol. 244, no. 1, pp. 1–14, 1997. View at Scopus
  4. A. E. Jeukendrup, W. H. Saris, and A. J. Wagenmakers, “Fat metabolism during exercise: a review—part II: regulation of metabolism and the effects of training,” International Journal of Sports Medicine, vol. 19, no. 5, pp. 293–302, 1998. View at Scopus
  5. R. J. A. Wanders, P. Vreken, M. E. J. Den Boer, F. A. Wijburg, A. H. Van Gennip, and L. IJlst, “Disorders of mitochondrial fatty acyl-CoA β-oxidation,” Journal of Inherited Metabolic Disease, vol. 22, no. 4, pp. 442–487, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Mitchell, “Chemiosmotic coupling in energy transduction: a logical development of biochemical knowledge,” Journal of Bioenergetics, vol. 3, no. 1-2, pp. 5–24, 1972. View at Publisher · View at Google Scholar · View at Scopus
  7. A. M. Das and D. A. Harris, “Intracellular calcium as a regulator of the mitochondrial ATP synthase in cultured cardiomyocytes,” Biochemical Society Transactions, vol. 18, no. 4, pp. 554–555, 1990. View at Scopus
  8. A. M. Das and D. A. Harris, “Regulation of the mitochondrial ATP synthase in intact rat cardiomyocytes,” Biochemical Journal, vol. 266, no. 2, pp. 355–361, 1990. View at Scopus
  9. A. M. Das, “Regulation of the mitochondrial ATP-synthase in health and disease,” Molecular Genetics and Metabolism, vol. 79, no. 2, pp. 71–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. D. A. Harris and A. M. Das, “Control of mitochondrial ATP synthesis in the heart,” Biochemical Journal, vol. 280, part 3, pp. 561–573, 1991. View at Scopus
  11. A. M. Das, “Regulation of mitochondrial ATP synthase activity in human myocardium,” Clinical Science, vol. 94, no. 5, pp. 499–504, 1998. View at Scopus
  12. E. W. Yamada and N. J. Huzel, “The calcium-binding ATPase inhibitor protein from bovine heart mitochondria. Purification and properties,” Journal of Biological Chemistry, vol. 263, no. 23, pp. 11498–11503, 1988. View at Scopus
  13. A. M. Das and D. A. Harris, “Control of mitochondrial ATP synthase in rat cardiomyocytes: effects of thyroid hormone,” Biochimica et Biophysica Acta, vol. 1096, no. 4, pp. 284–290, 1991. View at Publisher · View at Google Scholar · View at Scopus
  14. A. M. Das and D. A. Harris, “Mitochondrial ATP synthase regulation in heart: defects in hypertension are restored after treatment with captopril,” Cardioscience, vol. 3, no. 4, pp. 227–232, 1992. View at Scopus
  15. A. M. Das and D. A. Harris, “Regulation of the mitochondrial ATP synthase is defective in rat heart during alcohol-induced cardiomyopathy,” Biochimica et Biophysica Acta, vol. 1181, no. 3, pp. 295–299, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. A. M. Das and D. A. Harris, “Defects in regulation of mitochondrial ATP synthase in cardiomyocytes from spontaneously hypertensive rats,” American Journal of Physiology, vol. 259, no. 4, part 2, pp. H1264–H1269, 1990. View at Scopus
  17. R. M. Denton, G. A. Rutter, P. J. Midgley, and J. G. McCormack, “Effects of Ca2+ on the activities of the calcium-sensitive dehydrogenases within the mitochondria of mammalian tissues,” Journal of Cardiovascular Pharmacology, vol. 12, no. 5, pp. S69–S72, 1988. View at Scopus
  18. J. G. McCormack and R. M. Denton, “The effects of calcium ions and adenine nucleotides on the activity of pig heart 2-oxoglutarate dehydrogenase complex,” Biochemical Journal, vol. 180, no. 3, pp. 533–544, 1979. View at Scopus
  19. R. M. Denton, “Regulation of mitochondrial dehydrogenases by calcium ions,” Biochimica et Biophysica Acta, vol. 1787, no. 11, pp. 1309–1316, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. D. Constantin-Teodosiu, N. S. Peirce, J. Fox, and P. L. Greenhaff, “Muscle pyruvate availability can limit the flux, but not activation, of the pyruvate dehydrogenase complex during submaximal exercise in humans,” The Journal of Physiology, vol. 561, no. 2, pp. 647–655, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. G. C. Brown, “Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase,” Biochimica et Biophysica Acta, vol. 1504, no. 1, pp. 46–57, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. G. C. Brown, “Nitric oxide and mitochondria,” Frontiers in Bioscience, vol. 12, no. 3, pp. 1024–1033, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. L. B. Valdez and A. Boveris, “Mitochondrial nitric oxide synthase, a voltage-dependent enzyme, is responsible for nitric oxide diffusion to cytosol,” Frontiers in Bioscience, vol. 12, no. 4, pp. 1210–1219, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. L. B. Valdez, T. Zaobornyj, and A. Boveris, “Mitochondrial metabolic states and membrane potential modulate mtNOS activity,” Biochimica et Biophysica Acta, vol. 1757, no. 3, pp. 166–172, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. N. Gordon, “Glycogenosis type V or McArdle's disease,” Developmental Medicine and Child Neurology, vol. 45, no. 9, pp. 640–644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Hanisch, K. Eger, S. Bork, H. Lehnich, M. Deschauer, and S. T. Zierz, “Lactate production upon short-term non-ischemic forearm exercise in mitochondrial disorders and other myopathies,” Journal of Neurology, vol. 253, no. 6, pp. 735–740, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. D. Bendahan, J. P. Mattéi, G. Kozak-Ribbens, and P. J. Cozzone, “Non invasive investigation of muscle diseases using P31 magnetic resonance spectroscopy: potential in clinical applications,” Revue Neurologique, vol. 158, no. 5, part 1, pp. 527–540, 2002. View at Scopus
  28. B. Barbiroli, R. Medori, H. J. Tritschler, et al., “Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo P31-MRS in a patient with mitochondrial cytopathy,” Journal of Neurology, vol. 242, no. 7, pp. 472–477, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. G. M. Fabrizi, R. Lodi, M. D'Ettorre, et al., “Autosomal dominant limb girdle myopathy with ragged-red fibers and cardiomyopathy a pedigree study by in vivo P31-MR spectroscopy indicating a multisystem mitochondrial defect,” Journal of the Neurological Sciences, vol. 137, no. 1, pp. 20–27, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. D. E. Befroy, K. Falk Petersen, D. L. Rothman, and G. I. Shulman, “Chapter 21 assessment of in vivo mitochondrial metabolism by magnetic resonance spectroscopy,” Methods in Enzymology, vol. 457, pp. 373–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Tashiro, T. Fujimoto, M. Itoh, et al., “F18-FDG PET imaging of muscle activity in runners,” Journal of Nuclear Medicine, vol. 40, no. 1, pp. 70–76, 1999. View at Scopus
  32. R. Santer, M. Kinner, U. Steuerwald, et al., “Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands,” European Journal of Human Genetics, vol. 9, no. 5, pp. 388–391, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. J. H. Ding, T. De Barsy, B. I. Brown, R. A. Coleman, and Y. T. Chen, “Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III,” The Journal of Pediatrics, vol. 116, no. 1, pp. 95–100, 1990. View at Publisher · View at Google Scholar · View at Scopus
  34. R. A. Coleman, H. S. Winter, B. Wolf, J. M. Gilchrist, and Y. T. Chen, “Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy,” Annals of Internal Medicine, vol. 116, no. 11, pp. 896–900, 1992. View at Scopus
  35. Y. Endo, A. Horinishi, M. Vorgerd, et al., “Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey,” Journal of Human Genetics, vol. 51, no. 11, pp. 958–963, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. S. Lucchiari, D. Santoro, S. Pagliarani, and G. P. Comi, “Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency,” Acta Myologica, vol. 26, no. 1, pp. 72–74, 2007. View at Scopus
  37. B. Schoser, D. Gläser, and J. Müller-Höcker, “Clinicopathological analysis of the homozygous p.W1327X AGL mutation in glycogen storage disease type 3,” American Journal of Medical Genetics, Part A, vol. 146, no. 22, pp. 2911–2915, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. E. Demo, D. Frush, M. Gottfried, et al., “Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?” Journal of Hepatology, vol. 46, no. 3, pp. 492–498, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. S. Kiechl, J. Willeit, W. Vogel, U. Kohlendorfer, and W. Poewe, “Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis,” Neuromuscular Disorders, vol. 9, no. 6-7, pp. 408–410, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Kiechl, U. Kohlendorfer, C. Thaler, et al., “Different clinical aspects of debrancher deficiency myopathy,” Journal of Neurology Neurosurgery and Psychiatry, vol. 67, no. 3, pp. 364–368, 1999. View at Scopus
  41. M. A. Kotb, H. K. Abdullah, and A. Kotb, “Liver glycogenoses: are they a possible cause of polyneuropathy? A cross-sectional study,” Journal of Tropical Pediatrics, vol. 50, no. 4, pp. 196–202, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. H. R. Mundy, J. E. Williams, P. J. Lee, and M. S. Fewtrell, “Reduction in bone mineral density in glycogenosis type III may be due to a mixed muscle and bone deficit,” Journal of Inherited Metabolic Disease, vol. 31, no. 3, pp. 418–423, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. H. Akazawa, T. Kuroda, S. Kim, H. Mito, T. Kojo, and K. Shimada, “Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy,” European Heart Journal, vol. 18, no. 3, pp. 532–533, 1997. View at Scopus
  44. H. Tada, T. Kurita, T. Ohe, et al., “Glycogen storage disease type III associated with ventricular tachycardia,” American Heart Journal, vol. 130, no. 4, pp. 911–912, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. P. J. Lee, J. E. Deanfield, M. Burch, K. Baig, W. J. McKenna, and J. V. Leonard, “Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III,” The American Journal of Cardiology, vol. 79, no. 6, pp. 834–838, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. J. J. Shen and Y. T. Chen, “Molecular characterization of glycogen storage disease type III,” Current Molecular Medicine, vol. 2, no. 2, pp. 167–175, 2002. View at Scopus
  47. Y. Aoyama, I. Ozer, M. Demirkol, et al., “Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations,” Journal of Human Genetics, vol. 54, no. 11, pp. 681–686, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. J. Seigel, D. A. Weinstein, R. Hillman, B. Colbert, B. Matthews, and B. Bachrach, “Glycogen storage disease type IIIa presenting as non-ketotic hypoglycemia: use of a newly approved commercially available mutation analysis to non-invasively confirm the diagnosis,” Journal of Pediatric Endocrinology and Metabolism, vol. 21, no. 6, pp. 587–590, 2008. View at Scopus
  49. A. I. Dagli, R. T. Zori, H. McCune, T. Ivsic, M. K. Maisenbacher, and D. A. Weinstein, “Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet,” Journal of Inherited Metabolic Disease, pp. 1–4, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. C. Bartram, R. H. T. Edwards, J. Clague, and R. J. Beynon, “McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases,” Human Molecular Genetics, vol. 2, no. 8, pp. 1291–1293, 1993. View at Scopus
  51. C. Kubisch, E. M. Wicklein, and T. J. Jentsch, “Molecular diagnosis of McArdle disease: revised genomic structure of the myophosphorylase gene and identification of a novel mutation,” Human Mutation, vol. 12, no. 1, pp. 27–32, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. A. L. Andreu, G. Nogales-Gadea, D. Cassandrini, J. Arenas, and C. Bruno, “McArdle disease: molecular genetic update,” Acta Myologica, vol. 26, no. 1, pp. 53–57, 2007. View at Scopus
  53. F. Gómez-Gallego, C. Santiago, M. Morán, et al., “The I allele of the ACE gene is associated with improved exercise capacity in women with McArdle disease,” British Journal of Sports Medicine, vol. 42, no. 2, pp. 134–140, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. A. Lucia, F. Gómez-Gallego, C. Santiago, et al., “The 577X allele of the ACTN3 gene is associated with improved exercise capacity in women with McArdle's disease,” Neuromuscular Disorders, vol. 17, no. 8, pp. 603–610, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. A. Martinuzzi, A. Liava, E. Trevisi, L. Antoniazzi, and M. Frare, “Chronic therapy for McArdle disease: the randomized trial with ACE inhibitor,” Acta Myologica, vol. 26, no. 1, pp. 64–66, 2007. View at Scopus
  56. B. Mcardle, “Myopathy due to a defect in muscle glycogen breakdown,” Clinical Science, vol. 10, pp. 13–33, 1951.
  57. A. A. Nadaj-Pakleza, C. M. Vincitorio, P. Laforêt, et al., “Permanent muscle weakness in McArdle disease,” Muscle and Nerve, vol. 40, no. 3, pp. 350–357, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. D. Bendahan, S. Confort-Gouny, G. Kozak-Ribbens, and P. J. Cozzone, “31-P NMR characterization of the metabolic anomalies associated with the lack of glycogen phosphorylase activity in human forearm muscle,” Biochemical and Biophysical Research Communications, vol. 185, no. 1, pp. 16–21, 1992. View at Publisher · View at Google Scholar · View at Scopus
  59. B. D. Ross, G. K. Radda, D. G. Gadian, G. Rocker, M. Esiri, and J. Falconer-Smith, “Examination of a case of suspected McArdle's syndrome by P31 nuclear magnetic resonance,” New England Journal of Medicine, vol. 304, no. 22, pp. 1338–1342, 1981. View at Scopus
  60. J. L. Fleckenstein, R. G. Haller, S. F. Lewis, et al., “Absence of exercise-induced MRI enhancement of skeletal muscle in McArdle's disease,” Journal of Applied Physiology, vol. 71, no. 3, pp. 961–969, 1991. View at Scopus
  61. R. Quinlivan, R. J. Beynon, and A. Martinuzzi, “Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V),” Cochrane Database of Systematic Reviews (Online), no. 2, Article ID CD003458, 2008. View at Scopus
  62. M. Vorgerd, T. Grehl, M. Jäger, et al., “Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial,” Archives of Neurology, vol. 57, no. 7, pp. 956–963, 2000. View at Scopus
  63. M. Vorgerd, J. Zange, R. Kley, et al., “Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study,” Archives of Neurology, vol. 59, no. 1, pp. 97–101, 2002. View at Scopus
  64. A. Toscano and O. Musumeci, “Tarui disease and distal glycogenoses: clinical and genetic update,” Acta Myologica, vol. 26, no. 2, pp. 105–107, 2007. View at Scopus
  65. S. Vora, “Isozymes of phosphofructokinase,” Isozymes, vol. 6, pp. 119–167, 1982. View at Scopus
  66. S. Tarui, G. Okuno, Y. Ikura, T. Tanaka, M. Suda, and M. Nishikawa, “Phosphofructokinase deficiency in skeletal muscle. A new type of glycogenosis,” Biochemical and Biophysical Research Communications, vol. 19, no. 4, pp. 517–523, 1965. View at Scopus
  67. D. Duboc, P. Jehenson, and S. T. Dinh, “Phosphorus NMR spectroscopy study of muscular enzyme deficiencies involving glycogenolysis and glycolysis,” Neurology, vol. 37, no. 4, pp. 663–671, 1987. View at Scopus
  68. Z. Argov, N. De Stefano, and D. L. Arnold, “Muscle high-energy phosphates in central nervous system disorders. The phosphorus MRS experience,” The Italian Journal of Neurological Sciences, vol. 18, no. 6, pp. 353–357, 1997. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Rinaldo, D. Matern, and M. J. Bennett, “Fatty acid oxidation disorders,” Annual Review of Physiology, vol. 64, pp. 477–502, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. S. DiMauro and P. M. M. DiMauro, “Muscle carnitine palmityltransferase deficiency and myoglobinuria,” Science, vol. 182, no. 4115, pp. 929–931, 1973. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Illsinger, T. Lücke, M. Peter, et al., “Carnitine-palmitoyltransferase 2 deficiency: novel mutations and relevance of newborn screening,” American Journal of Medical Genetics, Part A, vol. 146, no. 22, pp. 2925–2928, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. S. Corti, A. Bordoni, D. Ronchi, et al., “Clinical features and new molecular findings in Carnitine Palmitoyltransferase II (CPT II) deficiency,” Journal of the Neurological Sciences, vol. 266, no. 1-2, pp. 97–103, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. A. M. Das, R. Fingerhut, R. J. A. Wanders, and K. Ullrich, “Secondary respiratory chain defect in a boy with long-chain 3- hydroxyacyl-CoA dehydrogenase deficiency: possible diagnostic pitfalls,” European Journal of Pediatrics, vol. 159, no. 4, pp. 243–246, 2000. View at Scopus
  74. U. Spiekerkoetter, M. Lindner, R. Santer, et al., “Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop,” Journal of Inherited Metabolic Disease, vol. 32, no. 4, pp. 498–505, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. J. O. Solis and R. H. Singh, “Management of fatty acid oxidation disorders: a survey of current treatment strategies,” Journal of the American Dietetic Association, vol. 102, no. 12, pp. 1800–1803, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. U. Spiekerkoetter, M. Lindner, R. Santer, et al., “Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop,” Journal of Inherited Metabolic Disease, vol. 32, no. 4, pp. 488–497, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. M. B. Gillingham, B. Scott, D. Elliott, and C. O. Harding, “Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency,” Molecular Genetics and Metabolism, vol. 89, no. 1-2, pp. 58–63, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. M. B. Gillingham, J. Q. Purnell, J. Jordan, D. Stadler, A. M. Haqq, and C. O. Harding, “Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency,” Molecular Genetics and Metabolism, vol. 90, no. 1, pp. 64–69, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. C. R. Roe, L. Sweetman, D. S. Roe, F. David, and H. Brunengraber, “Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride,” Journal of Clinical Investigation, vol. 110, no. 2, pp. 259–269, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Gobin-Limballe, F. Djouadi, F. Aubey, et al., “Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy,” American Journal of Human Genetics, vol. 81, no. 6, pp. 1133–1143, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. A. Minnich, N. Tian, L. Byan, and G. Bilder, “A potent PPARα agonist stimulates mitochondrial fatty acid β-oxidation in liver and skeletal muscle,” American Journal of Physiology, vol. 280, no. 2, pp. E270–E279, 2001. View at Scopus
  82. F. Djouadi, F. Aubey, D. Schlemmer, et al., “Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs?” Journal of Inherited Metabolic Disease, vol. 29, no. 2-3, pp. 341–342, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. J. L. K. Van Hove, S. Grünewald, J. Jaeken, et al., “D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD),” Lancet, vol. 361, no. 9367, pp. 1433–1435, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. C. Gellera, E. Verderio, G. Floridia, et al., “Assignment of the human carnitine palmitoyltransferase II gene (CPT1) to chromosome 1p32,” Genomics, vol. 24, no. 1, pp. 195–197, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. M. Deschauer, T. Wieser, and S. Zierz, “Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects,” Archives of Neurology, vol. 62, no. 1, pp. 37–41, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. S. E. Olpin, A. Afifi, S. Clark, et al., “Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency,” Journal of Inherited Metabolic Disease, vol. 26, no. 6, pp. 543–557, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Hug, K. E. Bove, and S. Soukup, “Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II,” New England Journal of Medicine, vol. 325, no. 26, pp. 1862–1864, 1991. View at Scopus
  88. F. Taroni and G. Uziel, “Fatty acid mitochondrial β-oxidation and hypoglycaemia in children,” Current Opinion in Neurology, vol. 9, no. 6, pp. 477–485, 1996. View at Scopus
  89. F. Demaugre, J. P. Bonnefont, M. Colonna, C. Cepanec, J. P. Leroux, and J. M. Saudubray, “Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies,” Journal of Clinical Investigation, vol. 87, no. 3, pp. 859–864, 1991. View at Scopus
  90. L. Thuillier, H. Rostane, V. Droin, et al., “Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency,” Human Mutation, vol. 21, no. 5, pp. 493–501, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. G. D. Vladutiu, M. J. Bennett, D. Smail, L. J. Wong, R. T. Taggart, and H. B. Lindsley, “A variable myopathy associated with heterozygosity for the R503C mutation in the carnitine palmitoyltransferase II gene,” Molecular Genetics and Metabolism, vol. 70, no. 2, pp. 134–141, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. L. Thuillier, C. Sevin, F. Demaugre, et al., “Genotype/phenotype correlation in carnitine palmitoyl transferase II deficiency: lessons from a compound heterozygous patient,” Neuromuscular Disorders, vol. 10, no. 3, pp. 200–205, 2000. View at Publisher · View at Google Scholar · View at Scopus
  93. P. J. Isackson, M. J. Bennett, and G. D. Vladutiu, “Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency,” Molecular Genetics and Metabolism, vol. 89, no. 4, pp. 323–331, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. P. J. Isackson, M. J. Bennett, U. Lichter-Konecki, et al., “CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency,” Molecular Genetics and Metabolism, vol. 94, no. 4, pp. 422–427, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. J. P. Bonnefont, F. Taroni, P. Cavadini, et al., “Molecular analysis of carnitine palmitoyltransferase II deficiency with hepatocardiomuscular expression,” American Journal of Human Genetics, vol. 58, no. 5, pp. 971–978, 1996. View at Scopus
  96. U. Spiekerkoetter, Z. Khuchua, Z. Yue, M. J. Bennett, and A. W. Strauss, “General mitochondrial trifunctional protein (TFP) deficiency as a result of either α- or β-subunit mutations exhibits similar phenotypes because mutations in either subunit alter TFP complex expression and subunit turnover,” Pediatric Research, vol. 55, no. 2, pp. 190–196, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. R. J. A. Wanders, L. Ijlst, F. Poggi, et al., “Human trifunctional protein deficiency: a new disorder of mitochondrial fatty acid β-oxidation,” Biochemical and Biophysical Research Communications, vol. 188, no. 3, pp. 1139–1145, 1992. View at Publisher · View at Google Scholar · View at Scopus
  98. A. M. Das, S. Illsinger, T. Lücke, et al., “Isolated mitochondrial long-chain ketoacyl-CoA thiolase deficiency resulting from mutations in the HADHB gene,” Clinical Chemistry, vol. 52, no. 3, pp. 530–534, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. O. Scheuerman, R. J. A. Wanders, H. R. Waterham, G. Dubnov-Raz, and B.-Z. Garty, “Mitochondrial trifunctional protein deficiency with recurrent rhabdomyolysis,” Pediatric Neurology, vol. 40, no. 6, pp. 465–467, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. M. E. J. Den Boer, C. Dionisi-Vici, A. Chakrapani, A. O. J. Van Thuijl, R. J. A. Wanders, and F. A. Wijburg, “Mitochondrial trifunctional protein deficiency: a severe fatty acid oxidation disorder with cardiac and neurologic involvement,” The Journal of Pediatrics, vol. 142, no. 6, pp. 684–689, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. K. Izai, Y. Uchida, T. Orii, S. Yamamoto, and T. Hashimoto, “Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acyl-coenzyme A dehydrogenase,” The Journal of Biological Chemistry, vol. 267, no. 2, pp. 1027–1033, 1992.
  102. B. S. Andresen, S. Olpin, B. J. H. M. Poorthuis, et al., “Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency,” American Journal of Human Genetics, vol. 64, no. 2, pp. 479–494, 1999. View at Scopus
  103. B. S. Andresen, C. Vianey-Saban, P. Bross, et al., “The mutational spectrum in very long-chain acyl-CoA dehydrogenase deficiency,” Journal of Inherited Metabolic Disease, vol. 19, no. 2, pp. 169–172, 1996. View at Publisher · View at Google Scholar · View at Scopus
  104. C. Bertrand, C. Largilliere, M. T. Zabot, M. Mathieu, and C. Vianey-Saban, “Very long chain acyl-CoA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid oxidation in fibroblasts,” Biochimica et Biophysica Acta, vol. 1180, no. 3, pp. 327–329, 1993. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Vianey-Saban, P. Divry, M. Brivet, et al., “Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients,” Clinica Chimica Acta, vol. 269, no. 1, pp. 43–62, 1998. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Kluge, P. Kühnelt, A. Block, et al., “A young woman with persistent hypoglycemia, rhabdomyolysis, and coma: recognizing fatty acid oxidation defects in adults,” Critical Care Medicine, vol. 31, no. 4, pp. 1273–1276, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. A. Boneh, B. S. Andresen, N. Gregersen, et al., “VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis,” Molecular Genetics and Metabolism, vol. 88, no. 2, pp. 166–170, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. J. D. Hoffman, R. D. Steiner, L. Paradise, et al., “Rhabdomyolysis in the military: recognizing late-onset very long-chain acyl Co-A dehydrogenase deficiency,” Military Medicine, vol. 171, no. 7, pp. 657–658, 2006. View at Scopus
  109. B. Merinero, S. I. Pascual Pascual, C. Pérez-Cerdá, et al., “Adolescent myopathic presentation in two sisters with very long-chain acyl-CoA dehydrogenase deficiency,” Journal of Inherited Metabolic Disease, vol. 22, no. 7, pp. 802–810, 1999. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Minetti, B. Garavaglia, M. Bado, et al., “Very-long-chain acyl-coenzyme A dehydrogenase deficiency in a child with recurrent myoglobinuria,” Neuromuscular Disorders, vol. 8, no. 1, pp. 3–6, 1998. View at Publisher · View at Google Scholar · View at Scopus
  111. I. Ogilvie, M. Pourfarzam, S. Jackson, C. Stockdale, K. Bartlett, and D. M. Turnbull, “Very long-chain acyl coenzyme A dehydrogenase deficiency presenting with exercise-induced myoglobinuria,” Neurology, vol. 44, no. 3, part 1, pp. 467–473, 1994. View at Scopus
  112. R. Pons, P. Cavadini, S. Baratta, et al., “Clinical and molecular heterogeneity in very-long-chain acyl-coenzyme A dehydrogenase deficiency,” Pediatric Neurology, vol. 22, no. 2, pp. 98–105, 2000. View at Publisher · View at Google Scholar · View at Scopus
  113. H. R. Scholte, R. N. A. Van Coster, P. C. De Jonge, et al., “Myopathy in very-long-chain acyl-CoA dehydrogenase deficiency: clinical and biochemical differences with the fatal cardiac phenotype,” Neuromuscular Disorders, vol. 9, no. 5, pp. 313–319, 1999. View at Publisher · View at Google Scholar · View at Scopus
  114. A. H. M. Smelt, B. J. H. M. Poorthuis, W. Onkenhout, et al., “Very long chain acyl-coenzyme A dehydrogenase deficiency with adult onset,” Annals of Neurology, vol. 43, no. 4, pp. 540–544, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. N. C. Voermans, B. G. van Engelen, L. A. Kluijtmans, N. M. Stikkelbroeck, and A. R. Hermus, “Rhabdomyolysis caused by an inherited metabolic disease: very long-chain Acyl-CoA dehydrogenase deficiency,” American Journal of Medicine, vol. 119, no. 2, pp. 176–179, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. A. Zia, E. H. Kolodny, and G. M. Pastores, “Very long chain acyl-CoA dehydrogenase deficiency in a pair of mildly affected monozygotic twin sister in their late fifties,” Journal of Inherited Metabolic Disease, vol. 30, no. 5, p. 817, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. P. Laforêt, C. Acquaviva-Bourdain, O. Rigal, et al., “Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency,” Neuromuscular Disorders, vol. 19, no. 5, pp. 324–329, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. F. E. Frerman and S. I. Goodman, “Defects of electron transfer flavoprotein and electron transfer flavoprotein-ubiquinone oxidoreductase: glutaric acidaemia type II,” in The Metabolic and Molecular Bases of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, Eds., pp. 2357–2365, McGraw-Hill, New York, NY, USA, 8th edition, 2001.
  119. R. K. J. Olsen, M. Pourfarzam, A. A. M. Morris, et al., “Lipid-storage myopathy and respiratory insufficiency due to ETFQO mutations in a patient with late-onset multiple acyl-CoA dehydrogenation deficiency,” Journal of Inherited Metabolic Disease, vol. 27, no. 5, pp. 671–678, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. E. Christensen, S. Kolvraa, and N. Gregersen, “Glutaric aciduria type II: evidence for a defect related to the electron transfer flavoprotein or its dehydrogenase,” Pediatric Research, vol. 18, no. 7, pp. 663–667, 1984. View at Scopus
  121. N. Gregersen, B. S. Andresen, C. B. Pedersen, R. K. J. Olsen, T. J. Corydon, and P. Bross, “Mitochondrial fatty acid oxidation defects—remaining challenges,” Journal of Inherited Metabolic Disease, vol. 31, no. 5, pp. 643–657, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  122. R. K. J. Olsen, S. E. Olpin, B. S. Andresen, et al., “ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency,” Brain, vol. 130, no. 8, pp. 2045–2054, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. B. Wen, T. Dai, W. Li, et al., “Riboflavin-responsive lipid-storage myopathy caused by ETFDH gene mutations,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 2, pp. 231–236, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. J. Bremer, “Carnitine—metabolism and functions,” Physiological Reviews, vol. 63, no. 4, pp. 1420–1480, 1983. View at Scopus
  125. I. Tein, “Carnitine transport: pathophysiology and metabolism of known molecular defects,” Journal of Inherited Metabolic Disease, vol. 26, no. 2-3, pp. 147–169, 2003. View at Scopus
  126. P. Rinaldo, C. A. Stanley, B. Y. L. Hsu, L. A. Sanchez, and H. J. Stern, “Sudden neonatal death in carnitine transporter deficiency,” The Journal of Pediatrics, vol. 131, no. 2, pp. 304–305, 1997. View at Publisher · View at Google Scholar · View at Scopus
  127. C. A. Stanley, S. DeLeeuw, P. M. Coates, et al., “Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake,” Annals of Neurology, vol. 30, no. 5, pp. 709–716, 1991. View at Scopus
  128. R. Pons and D. C. De Vivo, “Primary and secondary carnitine deficiency syndromes,” Journal of Child Neurology, vol. 10, supplement 2, pp. S8–S24, 1995. View at Scopus
  129. I. Tein, D. C. De Vivo, F. Bierman, et al., “Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy,” Pediatric Research, vol. 28, no. 3, pp. 247–255, 1990. View at Scopus
  130. A. M. Lamhonwah, S. E. Olpin, R. J. Pollitt, et al., “Novel OCTN2 mutations: No genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy,” American Journal of Medical Genetics, vol. 111, no. 3, pp. 271–284, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. R. S. Rijlaarsdam, F. J. van Spronsen, M. T. H. E. Bink-Boelkens, et al., “Ventricular fibrillation without overt cardiomyopathy as first presentation of organic cation transporter 2-deficiency in adolescence,” Pacing and Clinical Electrophysiology, vol. 27, no. 5, pp. 675–676, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. S. Vielhaber, H. Feistner, J. Weis, et al., “Primary carnitine deficiency: adult onset lipid storage myopathy with a mild clinical course,” Journal of Clinical Neuroscience, vol. 11, no. 8, pp. 919–924, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. U. Spiekerkoetter, G. Huener, T. Baykal, et al., “Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2,” Journal of Inherited Metabolic Disease, vol. 26, no. 6, pp. 613–615, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Vijay, A. Patterson, S. Olpin, et al., “Carnitine transporter defect: diagnosis in asymptomatic adult women following analysis of acylcarnitines in their newborn infants,” Journal of Inherited Metabolic Disease, vol. 29, no. 5, pp. 627–630, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. Y. Wang, S. H. Korman, J. Ye, et al., “Phenotype and genotype variation in primary carnitine deficiency,” Genetics in Medicine, vol. 3, no. 6, pp. 387–392, 2001. View at Scopus
  136. A. M. Das and D. A. Harris, “Control of mitochondrial ATP synthase in heart cells: inactive to active transitions caused by beating or positive inotropic agents,” Cardiovascular Research, vol. 24, no. 5, pp. 411–417, 1990. View at Scopus
  137. A. M. Das and D. J. Byrd, “Regulation of the mitochondrial ATP-synthase in skeletal muscle from children—a new diagnostic tool,” Journal of Inherited Metabolic Disease, vol. 19, no. 2, pp. 137–139, 1996. View at Publisher · View at Google Scholar
  138. D. G. Nicholls and S. L. Budd, “Mitochondria and neuronal survival,” Physiological Reviews, vol. 80, no. 1, pp. 315–360, 2000. View at Scopus
  139. S. Raha and B. H. Robinson, “Mitochondria, oxygen free radicals, and apoptosis,” American Journal of Medical Genetics, vol. 106, no. 1, pp. 62–70, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. R. Luft, D. Ikkos, G. Palmieri, L. Ernster, and B. Afzelius, “A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study,” The Journal of Clinical Investigation, vol. 41, no. 9, pp. 1776–1804, 1962. View at Publisher · View at Google Scholar · View at PubMed
  141. L. Ernster and R. Luft, “Further studies on a population of human skeletal muscle mitochondria lacking respiratory control,” Experimental Cell Research, vol. 32, no. 1, pp. 26–35, 1963. View at Scopus
  142. F. G. Debray, G. A. Mitchell, P. Allard, B. H. Robinson, J. A. Hanley, and M. Lambert, “Diagnostic accuracy of blood lactate-to-pyruvate molar ratio in the differential diagnosis of congenital lactic acidosis,” Clinical Chemistry, vol. 53, no. 5, pp. 916–921, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  143. B. H. Robinson, D. M. Glerum, W. Chow, R. Petrova-Benedict, R. Lightowlers, and R. Capaldi, “The use of skin fibroblast cultures in the detection of respiratory chain defects in patients with lacticacidemia,” Pediatric Research, vol. 28, no. 5, pp. 549–555, 1990. View at Scopus
  144. N. Mackay and B. H. Robinson, “Measurement of the ratio of lactate to pyruvate in skin fibroblast cultures,” Methods in Cell Biology, vol. 80, pp. 173–178, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  145. A. M. Das and K. Ullrich, “Dysregulation of the mitochondrial ATP-synthase in respiratory chain defects: first experience,” Journal of Inherited Metabolic Disease, vol. 21, no. 3, pp. 220–223, 1998. View at Publisher · View at Google Scholar · View at Scopus
  146. A. Abadi, E. I. Glover, R. J. Isfort, et al., “Limb immobilization induces a coordinate down-regulation of mitochondrial and other metabolic pathways in men and women,” PLoS One, vol. 4, no. 8, Article ID e6518, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  147. L.-J. C. Wong, “Comprehensive molecular diagnosis of mitochondrial disorders: qualitative and quantitative approach,” Annals of the New York Academy of Sciences, vol. 1011, pp. 246–258, 2004. View at Publisher · View at Google Scholar · View at Scopus
  148. L.-J. C. Wong, “Diagnostic challenges of mitochondrial DNA disorders,” Mitochondrion, vol. 7, no. 1-2, pp. 45–52, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  149. C. T. Moraes, S. Shanske, H. J. Tritschler, et al., “mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases,” American Journal of Human Genetics, vol. 48, no. 3, pp. 492–501, 1991. View at Scopus
  150. W. Sperl, D. Skladal, E. Gnaiger, et al., “High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders,” Molecular and Cellular Biochemistry, vol. 174, no. 1-2, pp. 71–78, 1997. View at Publisher · View at Google Scholar · View at Scopus
  151. S. Vielhaber, A. Kudin, R. Schröder, C. E. Elger, and W. S. Kunz, “Muscle fibres: applications for the study of the metabolic consequences of enzyme deficiencies in skeletal muscle,” Biochemical Society Transactions, vol. 28, no. 2, pp. 159–164, 2000. View at Scopus
  152. J. M. Cameron, V. Levandovskiy, N. MacKay, et al., “Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts,” Molecular Genetics and Metabolism, vol. 98, no. 4, pp. 378–382, 2009. View at Publisher · View at Google Scholar · View at PubMed
  153. M. E. McCue, S. J. Valberg, M. B. Miller, et al., “Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis,” Genomics, vol. 91, no. 5, pp. 458–466, 2008. View at Publisher · View at Google Scholar · View at PubMed
  154. W. I. M. Wuyts, E. Reyniers, C. Ceuterick, K. Storm, T. De Barsy, and J. J. Martin, “Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene,” American Journal of Medical Genetics, vol. 133, no. 1, pp. 82–84, 2005. View at Publisher · View at Google Scholar · View at PubMed
  155. M. C. Ørngreen, H. J. Schelhaas, T. D. Jeppesen, et al., “Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency?” Neurology, vol. 70, no. 20, pp. 1876–1882, 2008. View at Publisher · View at Google Scholar · View at PubMed
  156. B. T. Poll-The, J. Aicardi, R. Girot, and R. Rosa, “Neurological findings in triosephosphate isomerase deficiency,” Annals of Neurology, vol. 17, no. 5, pp. 439–443, 1985.
  157. R. Spiegel, E. A. Gomez, H. O. Akman, S. Krishna, Y. Horovitz, and S. DiMauro, “Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations,” Neuromuscular Disorders, vol. 19, no. 3, pp. 207–211, 2009. View at Publisher · View at Google Scholar · View at PubMed
  158. S. J. Oh, K. S. Park, H. F. Ryan, et al., “Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency,” Muscle and Nerve, vol. 34, no. 5, pp. 572–576, 2006. View at Publisher · View at Google Scholar · View at PubMed
  159. G. P. Comi, F. Fortunato, S. Lucchiari, et al., “β-enolase deficiency, a new metabolic myopathy of distal glycolysis,” Annals of Neurology, vol. 50, no. 2, pp. 202–207, 2001. View at Publisher · View at Google Scholar
  160. T. E. Nelson, “Malignant hyperthermia: a pharmacogenetic disease of Ca regulating proteins,” Current Molecular Medicine, vol. 2, no. 4, pp. 347–369, 2002. View at Publisher · View at Google Scholar
  161. M. Steinfath, F. Wappler, and J. Scholz, “Malignant hyperthermia. General, clinical and experimental aspects,” Der Anaesthesist, vol. 51, no. 4, pp. 328–345, 2002.
  162. H. Rosenberg, M. Davis, D. James, N. Pollock, and K. Stowell, “Malignant hyperthermia,” Orphanet Journal of Rare Diseases, vol. 2, article 21, 2007. View at Publisher · View at Google Scholar · View at PubMed
  163. G. D. Vladutiu, K. Hogan, I. Saponara, L. Tassini, and J. Conroy, “Carnitine palmitoyl transferase deficiency in malignant hyperthermia,” Muscle and Nerve, vol. 16, no. 5, pp. 485–491, 1993.
  164. A. K. W. Brownell, “Malignant hyperthermia: relationship to other diseases,” British Journal of Anaesthesia, vol. 60, no. 3, pp. 303–308, 1988.
  165. E. W. S. Cheam and L. A. H. Critchley, “Anesthesia for a child with complex I respiratory chain enzyme deficiency,” Journal of Clinical Anesthesia, vol. 10, no. 6, pp. 524–527, 1998. View at Publisher · View at Google Scholar
  166. J. Benca and K. Hogan, “Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options,” Anesthesia and Analgesia, vol. 109, no. 4, pp. 1049–1053, 2009. View at Publisher · View at Google Scholar · View at PubMed
  167. G. M. Hall, S. J. Kirtland, and H. Baum, “The inhibition of mitochondrial respiration by inhalational anaesthetic agents,” British Journal of Anaesthesia, vol. 45, no. 10, pp. 1005–1009, 1973.
  168. G. G. Duthie and J. R. Arthur, “Free radicals and calcium homeostasis: relevance to malignant hyperthermia?” Free Radical Biology and Medicine, vol. 14, no. 4, pp. 435–442, 1993. View at Publisher · View at Google Scholar
  169. J. Rahbek, B. Werge, A. Madsen, J. Marquardt, B. F. Steffensen, and J. Jeppesen, “Adult life with Duchenne muscular dystrophy: observations among an emerging and unforeseen patient population,” Pediatric Rehabilitation, vol. 8, no. 1, pp. 17–28, 2005. View at Publisher · View at Google Scholar
  170. E.-M. Strehle, “Long-term management of children with neuromuscular disorders,” Jornal de Pediatria, vol. 85, no. 5, pp. 379–384, 2009. View at Publisher · View at Google Scholar · View at PubMed